A Phase 1 interventional study of Extended-Release Methylphenidate in Sickle Cell Disease, Executive Dysfunction and Cognitive Impairment, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by St. Jude Children's Research Hospital · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital — 15 open to participants now, 17 under way, none of them phase 3. Anemia, Sickle Cell · St. Jude Children's Research Hospital.
Among the 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital, this one is the 7th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 1, reaches primary completion later than 6 of the 16 other live ones, and was the 42nd registered.
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
Browse Anemia, Sickle Cell studies →15 of the 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital are open now, in 2 countries. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in Mozambique
Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
Ages up to 22
St. Jude Children's Research Hospital · Sites in United States
Ages 10–18 · Women only · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
Ages 42 mo–78 mo
St. Jude Children's Research Hospital · Sites in United States
Ages 18–24
By country, each count listing its studies:
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 8 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 1992; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is above the median of 40 across 770 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 45 across the 22 interventional studies, 88 across the 23 observational. Of the 27 that completed or were terminated, 8 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
St. Jude Children's Research Hospital is the lead sponsor of 441 studies on the registry; 103 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 37 (61%) have results posted.
4 of the studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03353584St. Jude Children's Research HospitalEffect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease | 2026-11 |
| NCT06477289St. Jude Children's Research HospitalPeripheral Arterial Tonometry and Neurocognition in Sickle Cell Disease | 2027-06 |
| NCT07226219St. Jude Children's Research HospitalMethylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease | 2027-07-01 |
| NCT05583721St. Jude Children's Research HospitalRelationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects.
The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not.
Primary Objective:
Secondary Objective:
Exploratory Objective:
Children with sickle cell disease (SCD) are at higher risk for executive functioning (EF) deficits, including attention, working memory, and inhibitory control. These deficits are associated with poor academic performance, reduced quality of life, and challenges transitioning to adult healthcare. Despite the effectiveness of stimulant medications like methylphenidate (MPH) in improving EF in the general population and other medical groups, their use in children with SCD is rare.
This is a single-arm, open-label pilot trial conducted at St. Jude Children's Research Hospital. Thirty children with SCD and EF deficits will receive a 4-week course of extended-release MPH (10 mg or 20 mg daily, based on weight). Extended-release methylphenidate will be administered once daily for 4 weeks. The initial dose will be given in clinic, followed by home administration. Adherence will be monitored via weekly video pill counts.
The study will enroll 30 patients aged 8.0 to 17.9 years with SCD and EF impairment, along with 30 caregivers. An additional 12 caregivers who decline participation will be interviewed to assess decision-making and treatment barriers.
Neurobehavioral assessments and side effect evaluations will be conducted at baseline, immediately post-dose, and weekly during the home medication phase. Caregivers will complete rating scales and interviews to assess treatment acceptability and decision-making.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Between the ages of 8.0 and 17.9 years
*Included if performance measure, rating scale or diagnostic criteria met (within the past 2 years):
*Score at or below a Standard Score of 85 (16th percentile) on any 2 out of 4 performance measures:
*Score at or above a T Score of 60 (84th percentile) on any 1 out of 2 parent rating scales:
Exclusion Criteria:
Blood pressure >95th percentile at the three most recent visits consecutively (i.e., >95th percentile reading at all three of the most recent hospital visits to St. Jude).
Currently prescribed any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants in this single-arm pilot study will receive extended-release methylphenidate for 4 weeks. The intervention is designed to evaluate feasibility, acceptability, adherence, and safety of stimulant treatment in children and adolescents with sickle cell disease (SCD) and executive functioning deficits.
Drug: Extended-Release Methylphenidate
Participants will receive a weight-based dose of extended-release methylphenidate (0.6 mg/kg/day), rounded to either 10 mg or 20 mg, taken orally once daily for 4 weeks.
Also known as: MPH
Assess feasibility of methylphenidate
Feasibility is measured by the participation rate (i.e., ratio of those who agree to participate to those approached).
Time frame: Feasibility is measured during the initial recruitment process for each participant.
Assess acceptability of methylphenidate
Acceptability is captured by parent- and self-report ratings on the Acceptability of Intervention Measure (AIM).
Time frame: Acceptability ratings are captured at baseline and after 4 weeks of treatment with methylphenidate.
Assess adherence to methylphenidate
Adherence is measured through weekly pill counts. The primary adherence outcome is the ratio of the number of pills taken to those dispersed.
Time frame: Adherence is measured on a weekly basis through 4 weeks of treatment
Behavior Assessment System for Children, 3rd Edition (BASC-3), Parent Report
Attention, Hyperactivity, and Depression scales are calculated. The investigators will determine the amount and pattern of missing data. The relative change (defined as (post - pre)/pre)) will be calculated for each outcome and rank these changes to determine sensitivity of the measures. The goal of measuring neurobehavioral outcomes in this pilot trial is to determine how feasible the measures are for the target population and their relative sensitivity to the effects of methylphenidate treatment.
Time frame: Baseline and 4-6 weeks after treatment
Behavior Rating Inventory of Executive Function, 2nd Edition (BRIEF-2), Parent Report
Global Executive Composite Scale is calculated. The investigator will determine the amount and pattern of missing data for neurobehavioral outcomes. The relative change (defined as (post - pre)/pre)) will be calculated for each outcome and rank these changes to determine sensitivity of the measures. The goal of measuring neurobehavioral outcomes in this pilot trial is to determine how feasible the measures are for the target population and their relative sensitivity to the effects of methylphenidate treatment.
Time frame: Baseline and 4-6 weeks after treatment
Pediatric Quality of Life Inventory (PedsQL) Sickle Cell Disease modules, Parent Report
The investigator will determine the amount and pattern of missing data for neurobehavioral outcomes. The relative change (defined as (post - pre)/pre)) will be calculated for each outcome and rank these changes to determine sensitivity of the measures. The goal of measuring neurobehavioral outcomes in this pilot trial is to determine how feasible the measures are for the target population and their relative sensitivity to the effects of methylphenidate treatment.
Time frame: Baseline and 4-6 weeks after treatment
Pediatric Quality of Life Inventory (PedsQL) Multidimensional Fatigue modules, Parent Report
The investigator will determine the amount and pattern of missing data for neurobehavioral outcomes. The relative change (defined as (post - pre)/pre)) will be calculated for each outcome and rank these changes to determine sensitivity of the measures. The goal of measuring neurobehavioral outcomes in this pilot trial is to determine how feasible the measures are for the target population and their relative sensitivity to the effects of methylphenidate treatment.
Time frame: Baseline and 4-6 weeks after treatment
Conners 4th Edition Short Form, Self Report
The investigator will determine the amount and pattern of missing data for neurobehavioral outcomes. The relative change (defined as (post - pre)/pre)) will be calculated for each outcome and rank these changes to determine sensitivity of the measures. The goal of measuring neurobehavioral outcomes in this pilot trial is to determine how feasible the measures are for the target population and their relative sensitivity to the effects of methylphenidate treatment.
Time frame: Baseline and 4-6 weeks after treatment
NIH Toolbox Cognition
Dimensional Change Card Cort, Flanker, Pattern Comparison, Picture Sequence Memory Test, Picture Vocabulary subtests are completed. The investigator will determine the amount and pattern of missing data for neurobehavioral outcomes. The relative change (defined as (post - pre)/pre)) will be calculated for each outcome and rank these changes to determine sensitivity of the measures. The goal of measuring neurobehavioral outcomes in this pilot trial is to determine how feasible the measures are for the target population and their relative sensitivity to the effects of methylphenidate treatment.
Time frame: Baseline and ~90 minutes after first dose administered
Woodcock Johnson Tests of Academic Achievement, 4th Edition (WJ-IV)
Math Fluency subtest is completed. The investigator will determine the amount and pattern of missing data for neurobehavioral outcomes. The relative change (defined as (post - pre)/pre)) will be calculated for each outcome and rank these changes to determine sensitivity of the measures. The goal of measuring neurobehavioral outcomes in this pilot trial is to determine how feasible the measures are for the target population and their relative sensitivity to the effects of methylphenidate treatment.
Time frame: Baseline and ~90 minutes after first dose administered
Measure key safety outcomes using the Side Effects Rating Scale (SERS)
The investigator will record all adverse effects reported by participants and categorize adverse effects by type and severity based on the Side Effects Rating Scale. The investigator will present summary statistics, including the number of participants experiencing each type of adverse effect, the severity and the overall percentage of participants affected.
Time frame: Baseline in-clinic assessments followed by remote weekly assessments for 4 weeks
Measure key safety outcomes using the Systematic Assessment for Treatment Emergent Effects
The investigator will record all adverse effects reported by participants and categorize adverse effects by type and severity based on the Systematic Assessment for Treatment Emergent Effects. The investigator will present summary statistics, including the number of participants experiencing each type of adverse effect, the severity, and the overall percentage of participants affected
Time frame: Baseline in-clinic assessments followed by remote weekly assessments for 4 weeks
Evaluate decision-making and determinants influencing methylphenidate utilization among parents
Semi-structured interviews will be conducted. The interviews will be transcribed and qualitatively coded.
Time frame: Baseline and 4-6 weeks after treatment
Started Nov 2025 (actual). Primary completion is estimated for Jul 2027, 19 months after the start.
Of 58 phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 19 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methylphenidate
St. Jude Children's Research Hospital →